Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50.
Takei S, Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Katayama Y, Nishioka N, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K. Takei S, et al. Among authors: hasegawa i. Front Immunol. 2024 Feb 23;15:1348034. doi: 10.3389/fimmu.2024.1348034. eCollection 2024. Front Immunol. 2024. PMID: 38464519 Free PMC article.
An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer.
Yoshimura A, Uchino J, Tanimura K, Chihara Y, Tamiya N, Kaneko Y, Takeda T, Hiranuma O, Hasegawa I, Kubota Y, Shiotsu S, Takumi C, Hiraoka N, Yamada T, Takayama K. Yoshimura A, et al. Among authors: hasegawa i. Medicine (Baltimore). 2018 Oct;97(40):e12660. doi: 10.1097/MD.0000000000012660. Medicine (Baltimore). 2018. PMID: 30290647 Free PMC article.
Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study.
Shiotsu S, Yoshimura A, Yamada T, Morimoto K, Tsuchiya M, Yoshioka H, Hiranuma O, Chihara Y, Yamada T, Hasegawa I, Ohta T, Takeda T, Hiraoka N, Takayama K. Shiotsu S, et al. Among authors: hasegawa i. Front Oncol. 2022 Sep 9;12:904644. doi: 10.3389/fonc.2022.904644. eCollection 2022. Front Oncol. 2022. PMID: 36158655 Free PMC article.
Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer.
Morimoto K, Yamada T, Sawada R, Azuma K, Goto Y, Harada T, Shiotsu S, Tamiya N, Chihara Y, Takeda T, Hiranuma O, Hasegawa I, Tanaka S, Yoshimura A, Iwasaku M, Tokuda S, Kim YH, Takayama K. Morimoto K, et al. Among authors: hasegawa i. Cancer Immunol Immunother. 2023 Jun;72(6):1699-1707. doi: 10.1007/s00262-023-03370-1. Epub 2023 Jan 9. Cancer Immunol Immunother. 2023. PMID: 36617602 Free PMC article.
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Ishida M, Katayama Y, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K. Kawachi H, et al. Among authors: hasegawa i. JAMA Netw Open. 2023 Jul 3;6(7):e2322915. doi: 10.1001/jamanetworkopen.2023.22915. JAMA Netw Open. 2023. PMID: 37432682 Free PMC article.
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status.
Morimoto K, Yamada T, Kawachi H, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Nishioka N, Katayama Y, Iwasaku M, Tokuda S, Kijima T, Takayama K. Morimoto K, et al. Among authors: hasegawa i. Target Oncol. 2023 Nov;18(6):915-925. doi: 10.1007/s11523-023-01012-1. Epub 2023 Oct 30. Target Oncol. 2023. PMID: 37902896
Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.
Onoi K, Yamada T, Morimoto K, Kawachi H, Tsutsumi R, Takeda T, Okada A, Tamiya N, Chihara Y, Shiotsu S, Takemura Y, Yamada T, Hasegawa I, Katayama Y, Iwasaku M, Tokuda S, Takayama K. Onoi K, et al. Among authors: hasegawa i. Target Oncol. 2024 Mar 11. doi: 10.1007/s11523-024-01045-0. Online ahead of print. Target Oncol. 2024. PMID: 38467958
A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC.
Morimoto K, Sawada R, Yamada T, Azuma K, Ito K, Goto Y, Kimura H, Harada T, Shiotsu S, Tamiya N, Chihara Y, Takeda T, Hiranuma O, Hasegawa I, Morimoto Y, Iwasaku M, Tokuda S, Takayama K. Morimoto K, et al. Among authors: hasegawa i. JTO Clin Res Rep. 2022 Aug 6;3(9):100388. doi: 10.1016/j.jtocrr.2022.100388. eCollection 2022 Sep. JTO Clin Res Rep. 2022. PMID: 36082280 Free PMC article.
Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study.
Uda S, Yamada T, Yoshimura A, Goto Y, Yoshimine K, Nakamura Y, Shiotsu S, Yokoi T, Tamiya N, Kimura H, Chihara Y, Umeda Y, Izumi M, Takeda T, Yamada T, Hibino M, Hiranuma O, Ito K, Okada A, Osugi S, Takemura Y, Ishii H, Chibana K, Hasegawa I, Morimoto Y, Iwasaku M, Tokuda S, Takayama K. Uda S, et al. Among authors: hasegawa i. Transl Lung Cancer Res. 2022 Sep;11(9):1847-1857. doi: 10.21037/tlcr-22-160. Transl Lung Cancer Res. 2022. PMID: 36248326 Free PMC article.
TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study.
Katayama Y, Yamada T, Morimoto K, Fujii H, Morita S, Tanimura K, Takeda T, Okada A, Shiotsu S, Chihara Y, Hiranuma O, Yamada T, Ota T, Harada T, Hasegawa I, Yoshimura A, Iwasaku M, Tokuda S, Kim YH, Takayama K. Katayama Y, et al. Among authors: hasegawa i. JTO Clin Res Rep. 2023 Mar 7;4(4):100494. doi: 10.1016/j.jtocrr.2023.100494. eCollection 2023 Apr. JTO Clin Res Rep. 2023. PMID: 37020925 Free PMC article.
304 results